patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatoty and immuno-therapy - versus placebo - for COVID 19 outpatients
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 1.42 [0.38, 5.28]< 1 0% 5 studies (7/-) 30.2 % low not evaluable high crucial - deaths 0.59 [0.29, 1.22]< 1 0% 10 studies (12/-) 92.3 % low low high crucial - hospitalization or death 0.42 [0.26, 0.68]< 1 72% 8 studies (12/-) 100.0 % some concern serious moderate crucial - clinical deterioration 0.24 [0.10, 0.56]< 1 0% 1 study (1/-) 100.0 % NA not evaluable important - clinical improvement (14-day) 1.19 [0.78, 1.81]> 1 0% 1 study (1/-) 79.1 % NA not evaluable important - clinical improvement (28-day) 1.28 [0.84, 1.96]> 1 0% 1 study (1/-) 87.2 % NA not evaluable important - clinical improvement (7-day) 0.92 [0.51, 1.66]> 1 0% 1 study (1/-) 39.1 % NA not evaluable important - clinical improvement (time to event analysis only) 1.50 [1.30, 1.74]> 1 0% 1 study (1/-) 100.0 % NA not evaluable important - hospitalization 0.73 [0.51, 1.06]< 1 65% 7 studies (8/-) 95.2 % low not evaluable high important - mechanical ventilation 0.63 [0.29, 1.37]< 1 9% 2 studies (2/-) 87.6 % low not evaluable high important - Recovery (time to event analysis only) 1.50 [1.30, 1.74]> 1 0% 1 study (1/-) 100.0 % NA not evaluable important - symptomatic Covid-19 0.56 [0.31, 1.00]< 1 0% 1 study (1/-) 97.6 % NA not evaluable important - viral clearance 1.08 [0.45, 2.60]> 1 72% 2 studies (2/-) 56.6 % some concern not evaluable moderate important - viral clearance by day 7 1.45 [0.70, 2.99]> 1 44% 3 studies (4/-) 84.4 % some concern not evaluable moderate important - recovery 1.25 [0.71, 2.22]> 1 0% 1 study (1/-) 78.2 % NA not evaluable non important - 00 emergent treatment-resistant variants 0.64 [0.08, 4.94]< 1 67% 2 studies (2/-) 66.3 % some concern not evaluable moderate important - related AE (TRAE) 1.74 [1.50, 2.03]< 1 0% 1 study (1/-) 0.0 % NA not evaluable important - serious adverse events 0.75 [0.54, 1.05]< 1 2% 2 studies (2/-) 95.1 % low not evaluable high important - adverse events 0.76 [0.54, 1.06]< 1 43% 3 studies (3/-) 94.6 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration:
